Skip to main content
Clinical Trials/CTRI/2023/12/060574
CTRI/2023/12/060574
Not yet recruiting
未知

To evaluate the in-vivo safety and efficacy of the skin care formulation in terms of reduction in acne reduction in pore size, reduction in skin sebum content & improvement in skin brightness on healthy human subjects - NI

SATIYA NUTRACEUTICALS PRIVATE LIMITED0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
SATIYA NUTRACEUTICALS PRIVATE LIMITED
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
SATIYA NUTRACEUTICALS PRIVATE LIMITED

Eligibility Criteria

Inclusion Criteria

  • 1\)Skin is healthy on the studied anatomic unit
  • 2\)Having mild to moderate acne
  • 3\)Having mixed oily or oily skin on the face.
  • 4\)Having visible pores

Exclusion Criteria

  • 1\)For female: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months.Having refused to give her assent by signing the consent form.
  • 2\)Taking part in another study liable to interfere with this study.
  • 3\)Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area
  • 4\)Being insulin\-dependent diabetic or non insulin\-dependent diabetic with a recent therapy (less than 6 months)
  • 5\)Having a progressive asthma (either under treatment or last fit in the last 2 years)
  • 6\)Being epileptic
  • 7\)Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months)
  • 8\)Having cutaneous hypersensitivity
  • 9\)Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products or food products or to latex
  • 10\) Following a chronic medicinal treatment comprising any of the following products: aspirin\-based products, anti\-inflammatories, anti\-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol)

Outcomes

Primary Outcomes

Not specified

Similar Trials